Michael Levy

Director, Neuroimmunology Clinic and Research Laboratory · Mass General Brigham

Credentials: · · · · ·

History

Neuroimmunology Clinic and Research Laboratory · Mass General Brigham
Present
Division of Neuroimmunology & Neuroinfectious Disease · Mass General Brigham
Present
Division of Neuroimmunology & Neuroinfectious Disease · Massachusetts General Hospital
Present

Deep Phenotyping of DR15-Restricted CD4+ T Cells Specific for Epstein-Barr Virus Epitopes in the Spinal Fluid and Blood of People with Multiple Sclerosis
National Institute of Allergy and Infectious Diseases · R21
Contact PI · $247.5K · Massachusetts General Hospital
2026–2028
The Immunopathogenesis of Familial Transverse Myelitis Due to Mutations in VPS37a
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $1.7M · Massachusetts General Hospital
2023–2028
Spatiotemporal Tuning of Myelin Antigens and Rapamycin for Enhanced Antigen-Specific Immune Tolerance in Multiple Sclerosis.
National Institute of Allergy and Infectious Diseases · R43
PI · $295.1K · Statera Therapeutics Inc.
2021–2023
Developing Tolerization Therapies from a New T-Cell Based Mouse Model of Neuromyelitis Optica
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $2M · Massachusetts General Hospital
2018–2023

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders
Principal investigator · Withdrawn · Phase 2
Michael, Levy M.D.,Ph.D.
2026–2027
Effects of Antiviral Therapies on Epstein-Barr Virus Replication
Principal investigator · Enrolling by invitation · Phase 2
Massachusetts General Hospital
2023–2027
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
Principal investigator · Withdrawn · Phase 2
Massachusetts General Hospital
2022–2025
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
Principal investigator · Completed · Phase 2
Massachusetts General Hospital
2021–2025